AstraZeneca submitted an NDA to the FDA seeking approval for low-dose aspirin combined with esomeprazole magnesium (Nexium) to reduce the risk of low-dose aspirin-associated side effects, such as gastric and/or duodenal ulcers. AstraZeneca also submitted a sNDA for Nexium for the risk reduction of low-dose aspirin-associated gastric and/or duodenal ulcers. Nexium is approved for the risk reduction of gastric ulcers associated with continuous non-steroidal anti-inflammatory drug (NSAID) therap...